{
    "clinical_study": {
        "@rank": "38560", 
        "arm_group": [
            {
                "arm_group_label": "Concurrent Arm", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive sipuleucel-T concurrently with enzalutamide (160 mg orally once daily). Enzalutamide treatment will start 2 weeks prior to the first leukapheresis and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first."
            }, 
            {
                "arm_group_label": "Sequential Arm", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive sipuleucel-T followed by enzalutamide (160 mg orally once daily). Enzalutamide treatment will start approximately 10 weeks after the first infusion of sipuleucel-T and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, open-label study designed to assess the effects of sipuleucel-T when\n      administered concurrently or sequentially with enzalutamide."
        }, 
        "brief_title": "A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer", 
        "condition": "Metastatic Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, open-label study designed to assess the effects of sipuleucel-T when\n      administered concurrently or sequentially with enzalutamide. This study consists of 3\n      phases. The screening phase will begin at the completion of the informed consent process and\n      continue through registration. The active phase will begin at registration and continue\n      through the post-treatment visit (30 to 37 days following the last study treatment). The\n      long term follow-up (LTFU) phase will begin after the post-treatment visit and will continue\n      until the subject's death or until Dendreon terminates the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent provided prior to the initiation of study procedures.\n\n          -  Age \u2265 18 years.\n\n          -  Histologically documented adenocarcinoma prostate cancer confirmed by a pathology\n             report from prostate biopsy or a radical prostatectomy specimen.\n\n          -  Metastatic disease as evidenced by bone metastasis or lymph node metastasis.\n\n          -  Castrate-resistant prostate cancer as demonstrated by one of the following:\n\n               -  Prostate specific antigen progression.\n\n               -  Progression of measurable disease.\n\n               -  Progression of non-measurable disease by soft tissue disease or bone disease.\n\n          -  Castration levels of testosterone (\u2264 50 ng/dL) achieved via medical or surgical\n             castration.\n\n          -  Serum PSA \u2265 2.0 ng/mL.\n\n          -  Screening ECOG performance status \u2264 1\n\n          -  Adequate screening hematologic, renal, and liver function as evidenced by laboratory\n             test results obtained \u2264 28 days prior to registration.\n\n          -  Negative serology test for human immunodeficiency virus 1 and 2.\n\n          -  Resides within driving distance (round trip within 1 day) of the clinical trial site\n             for the duration of the active phase.\n\n        Exclusion Criteria:\n\n          -  The presence of known lung, liver, or brain metastases, malignant pleural effusions,\n             or malignant ascites.\n\n          -  Spinal cord compression, imminent long bone fracture, or any other condition that is\n             likely to require radiation therapy and/or steroids for pain control during the\n             active phase.\n\n          -  History of stage 3 or greater cancer, excluding prostate cancer. Basal or squamous\n             cell skin cancers must have been adequately treated and the subject must be disease\n             free at the time of registration. Subjects with a history of stage 1 or 2 cancer must\n             have been adequately treated and been disease free for \u2265 3 years at the time of\n             registration.\n\n          -  History of seizures or of predisposing factors for seizures.\n\n          -  Child-Pugh Class C hepatic insufficiency.\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to sipuleucel-T, GM-CSF or granulocyte colony stimulating factor (G-CSF).\n\n          -  Previous treatment with sipuleucel-T or enrollment in a sipuleucel-T trial,\n             regardless of whether the subject received sipuleucel-T or control.\n\n          -  Previous treatment with enzalutamide.\n\n          -  Previous treatment with abiraterone acetate.\n\n          -  Previous treatment with ipilimumab.\n\n          -  Previous treatment with ketoconazole other than topical use or for treatment of\n             infections (e.g., oral thrush); most recent use must have been \u2265 7 days prior to\n             registration.\n\n          -  Previous treatment with any immunotherapy or investigational vaccine.\n\n          -  A requirement for ongoing systemic immunosuppressive therapy. Use of inhaled,\n             intranasal, intra-articular, and topical steroids is allowed. Oral or IV steroids to\n             prevent or treat IV contrast reactions are allowed.\n\n          -  Previous treatment with chemotherapy for mCRPC, or chemotherapy for any reason \u2264 2\n             years prior to registration.\n\n          -  Use of concomitant medications that may lower the seizure threshold or the use of\n             antiseizure medications \u2264 1 year prior to registration.\n\n          -  Received GM-CSF or G-CSF \u2264 90 days prior to registration.\n\n          -  Ongoing non-steroidal antiandrogen withdrawal response.\n\n          -  Any of the following medications or interventions \u2264 28 days prior to registration:\n\n               -  Radiation therapy, either via external beam or brachytherapy.\n\n               -  Any systemic steroid. Use of inhaled, intra-nasal, intra-articular, and topical\n                  steroids is allowed. Oral or IV steroids to prevent or treat IV contrast\n                  reactions are allowed.\n\n               -  Any systemic therapy for prostate cancer, except for ADT.\n\n               -  Any investigational product for prostate cancer.\n\n               -  Major surgery requiring general anesthesia, with the exception of placement of\n                  central venous catheters.\n\n               -  Inducers and inhibitors of cytochrome P450 (CYP) enzyme CYP2C8 (gemfibrozil and\n                  rifampin).\n\n               -  Medications that are metabolized by CYP3A4, CYP2C9, or CYP2C19 that have a\n                  narrow therapeutic index.\n\n               -  Inducers of CYP3A4 (including but not limited to phenytoin, carbamazepine,\n                  rifampin, rifabutin, rifapentine, and phenobarbital).\n\n          -  A requirement for treatment with opioid analgesics for cancer-related pain \u2264 21 days\n             prior to registration.\n\n          -  An active infection requiring parenteral antibiotic therapy or causing fever\n             (temperature > 100.5\u02da F or 38.1\u02da C) \u2264 1 week prior to registration.\n\n          -  Any medical intervention, any other condition, or any other circumstance which could\n             compromise adherence with study requirements or otherwise compromise the study's\n             objectives."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981122", 
            "org_study_id": "P12-2"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Concurrent Arm", 
                    "Sequential Arm"
                ], 
                "description": "Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).", 
                "intervention_name": "sipuleucel-T", 
                "intervention_type": "Biological", 
                "other_name": [
                    "PROVENGE(R)", 
                    "APC8015"
                ]
            }, 
            {
                "arm_group_label": [
                    "Concurrent Arm", 
                    "Sequential Arm"
                ], 
                "description": "Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.", 
                "intervention_name": "enzalutamide", 
                "intervention_type": "Drug", 
                "other_name": "Xtandi"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85741"
                    }, 
                    "name": "Urological Associates of Southern Arizona, P.C."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "Zeno.Ashai@med.usc.edu", 
                    "last_name": "Zeno Ashai", 
                    "phone": "323-865-0463"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "USC/Norris Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "David Quinn, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80211"
                    }, 
                    "name": "The Urology Center of Colorado"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }, 
                    "name": "Yale University School of Medicine"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007"
                    }, 
                    "name": "Georgetown University Medical Center - Lombardi Cancer Center"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer and Research Center"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melrose Park", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60160"
                    }, 
                    "name": "Uro Partners/ RMD Clinical Research"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Wayne", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46804, 46845"
                    }, 
                    "name": "Fort Wayne Medical Oncology and Hematology, Lutheran Hospital, Parkview Regional Medical Center"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }, 
                    "name": "Johns Hopkins Medicine - Sidney Kimmel Comprehensive Cancer Center"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68130"
                    }, 
                    "name": "GU Research Network"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Setauket", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11733"
                    }, 
                    "name": "North Shore Hematology/Oncology Associates, P.C."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13210"
                    }, 
                    "name": "Associated Medical Professionals of New York, PLLC"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27607"
                    }, 
                    "name": "Raleigh Hematology Oncology Associates, D.B.A. Cancer Centers of North Carolina"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic - Taussig Cancer Institute"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Thomas Jefferson University"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Myrtle Beach", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29572"
                    }, 
                    "name": "Carolina Urologic Research Center"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37209"
                    }, 
                    "name": "Urology Associates, PC"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Virginia Beach", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23462"
                    }, 
                    "name": "Urology of Virginia"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98101"
                    }, 
                    "name": "Virginia Mason Medical Center, Virginia Mason Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98405"
                    }, 
                    "name": "Northwest Medical Specialties, Rainier Physicians"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer", 
        "overall_official": {
            "affiliation": "Dendreon", 
            "last_name": "Andy Sandler, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To evaluate peripheral PA2024-specific T cell immune response to sipuleucel-T over time via a T cell stimulation index from a proliferation assay.", 
            "safety_issue": "No", 
            "time_frame": "One year after the last subject completes 52 weeks of enzalutamide dosing."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981122"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To evaluate time to prostate-specific antigen (PSA) progression.", 
                "safety_issue": "No", 
                "time_frame": "One year after the last subject experiences PSA progression."
            }, 
            {
                "measure": "To estimate the percent of subjects who are PSA progression-free at 12 months.", 
                "safety_issue": "No", 
                "time_frame": "One year after the last subject completes 52 weeks of enzalutamide dosing."
            }, 
            {
                "measure": "To evaluate overall survival.", 
                "safety_issue": "No", 
                "time_frame": "One year after the last subject expires."
            }, 
            {
                "measure": "To evaluate the number of participants with Adverse Events and Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "One year after the last subject completes 52 weeks of enzalutamide dosing."
            }, 
            {
                "description": "To determine the magnitude of peripheral immune response over time as determined by the following:\nPeripheral PAP-specific T cell immune response to sipuleucel-T over time via a T cell stimulation index from a proliferation assay.\nT cell interferon-\u03b3 enzyme-linked immunosorbent spot assay (ELISPOT) response to PA2024 and PAP.\nHumoral response to PA2024 and PAP by enzyme-linked immunosorbent assay (ELISA).\nChemokine and cytokine production via fluorescent immunoassay (Luminex\u00ae assay).", 
                "measure": "To determine the magnitude of peripheral immune response over time.", 
                "safety_issue": "No", 
                "time_frame": "One year after the last subject completes 52 weeks of enzalutamide dosing."
            }
        ], 
        "source": "Dendreon", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dendreon", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}